Welcome to our dedicated page for DENTSPLY SIRONA news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on DENTSPLY SIRONA stock.
DENTSPLY SIRONA Inc. (symbol: XRAY) stands as the world’s largest manufacturer of professional dental products and technologies. As a global total solutions provider, Dentsply Sirona empowers dental professionals to offer better, safer, and faster dental care. The company’s extensive portfolio includes leading positions in consumables, equipment, technology, and specialty products. Dentsply Sirona is committed to innovation and quality, reflected in its comprehensive end-to-end solutions offering, which spans well-known and established brands in the industry.
Dentsply Sirona emerged from a merger between Dentsply International and Sirona Dental Systems in 2016. Today, the company manufactures and markets a complete range of dental and oral health products, including dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation.
Recently, Dentsply Sirona has announced enhancements to its DS Core platform, a cloud-based solution supporting dental professionals throughout the entire treatment continuum. The platform now boasts improved patient communication tools, a unified ordering system, and support for additional data formats, making it easier for dental practices to collaborate with labs and service providers.
Financially, Dentsply Sirona maintains a robust presence in the dental industry, with significant revenue generated through third-party distributors and direct sales to labs, offices, and consumers. The company’s ongoing commitment to innovation is further demonstrated by its DS World Las Vegas event, an annual gathering that provides dental professionals with market-leading education, networking opportunities, and exposure to the latest dental technologies.
With its headquarters in Charlotte, North Carolina, Dentsply Sirona continues to shape the future of dentistry, striving to enhance patient care and advance dental practices through its unwavering dedication to quality and innovation. For more information on Dentsply Sirona and its products, visit the official website.
DENTSPLY SIRONA (Nasdaq: XRAY) announced the conclusion of its internal investigation into financial reporting issues, resulting in restatements for Q3 2021 and full-year 2021. The Audit and Finance Committee identified material weaknesses in internal controls. The company expects a goodwill impairment charge between $1.0 billion and $1.3 billion due to economic factors. Preliminary Q3 2022 net sales are projected at $947 million, reflecting organic sales decline. DENTSPLY anticipates low-single-digit sequential net sales decline for Q4 2022 but expects flat growth on a constant currency basis.
Dentsply Sirona (Nasdaq: XRAY) has appointed Glenn Coleman as Executive Vice President and Chief Financial Officer, effective September 26, 2022. He succeeds Barbara Bodem, who served as Interim CFO since May 2022 and will assist Coleman until October 24, 2022. Coleman brings over 30 years of experience, having previously held executive roles at Integra Lifesciences and other global firms. CEO Simon Campion expressed confidence in Coleman’s leadership to enhance financial and operational strategies and support the company's growth initiatives.
Dentsply Sirona (Nasdaq: XRAY) unveiled new digital dentistry solutions at DS World 2022 in Las Vegas, aimed at enhancing efficiency and patient outcomes. A key feature is the Primescan Connect, a laptop-based intraoral scanner, designed for ease of use and integration. The product leverages the DS Core platform, enhancing connectivity and enabling streamlined workflows for treatment and diagnostics. Available from September 2022, these innovations promise to support dental practices in their operations while improving patient care.
Dentsply Sirona (Nasdaq: XRAY) announced the appointment of Simon Campion as President and CEO, effective September 12, 2022, succeeding John Groetelaars, who served as Interim CEO since April 2022. Campion joins from Becton, Dickinson and Company, bringing extensive experience in the medical device industry. His appointment is part of a strategic initiative to review and enhance the company's operations, competitive positioning, and capital structure. The Board highlighted Campion's record of operational expertise, sustainable growth, and potential to drive accountability and innovation.
Dentsply Sirona (Nasdaq: XRAY) announced on August 15, 2022, it remains non-compliant with Nasdaq Listing Rules, failing to file its Quarterly Reports on Form 10-Q for the first two quarters of 2022. Despite an earlier extension to file by August 14, the Company could not meet this deadline. An internal investigation regarding financial reporting matters is ongoing, complicating the filing process. Nasdaq may grant additional time to regain compliance, potentially extending the deadline to November 7, 2022. The notices received do not impact the current listing status of XRAY shares.
Dentsply Sirona (Nasdaq: XRAY) announced preliminary results for Q2 2022, expecting net sales over $1,005 million and adjusted EPS at or above $0.60. Despite year-over-year sales decline due to foreign exchange impacts, organic sales grew, driven by strong demand in Europe and recent product launches. An ongoing internal investigation into financial matters may delay the filing of its quarterly report. The company has declared a quarterly dividend of $0.125 per share, payable on October 14, 2022. Nasdaq compliance issues are also addressed, with an extension granted for filing the required reports.
DENTSPLY SIRONA Inc. (Nasdaq: XRAY) announced a quarterly cash dividend of $0.125 per share, indicating an annual rate of $0.50. This dividend is scheduled for payment on July 8, 2022, to shareholders of record as of June 24, 2022. Dentsply Sirona is recognized as the world’s largest manufacturer of professional dental products, providing innovative solutions that enhance patient care. The company has a strong portfolio of products and brands, reinforcing its commitment to the dental industry.
Dentsply Sirona (Nasdaq: XRAY) received a notification from Nasdaq on May 12, 2022, indicating non-compliance with listing rules due to the failure to file its Quarterly Report on Form 10-Q for the period ended March 31, 2022. The Company has 60 days to address this deficiency or submit a compliance plan. This notice does not immediately affect the stock's listing, and the Company aims to file the missing report as soon as possible. An investigation regarding the accounting of sales incentives is ongoing, which may have contributed to the delay.
Dentsply Sirona (Nasdaq: XRAY) reported Q1 2022 net sales of $965 million, a decrease of 6.1% from $1,027 million in Q1 2021. EPS dropped to $0.30, down 43.8%, while adjusted EPS decreased to $0.52 from $0.72. Operating income fell 39.5% to $93 million. Despite these declines, operating cash flow improved to $93 million. The company updated its FY2022 outlook, projecting organic sales growth of 2% to 3% and adjusted EPS between $2.35 and $2.55. Challenges stemmed from macroeconomic headwinds and weaker U.S. performance.
FAQ
What is the current stock price of DENTSPLY SIRONA (XRAY)?
What is the market cap of DENTSPLY SIRONA (XRAY)?
What does Dentsply Sirona Inc. do?
What is DS Core?
When was Dentsply Sirona formed?
Where is Dentsply Sirona headquartered?
What event does Dentsply Sirona host annually?
How can I learn more about Dentsply Sirona's products?
What kind of products does Dentsply Sirona offer?
What is the significance of Dentsply Sirona in the dental industry?
How does Dentsply Sirona distribute its products?
What recent updates has Dentsply Sirona announced?
